Table 1 Comparison of patient... | American Society of Hematology

Table 1

Comparison of patient characteristics in training and validation cohorts

	Training		Validation		P
	n	%	n	%	P
Total	143		144
Age (≥ 45 y)
No	118	83	122	85	.61
Yes	25	17	22	15
Sex
Female	63	44	63	44	.96
Male	80	56	81	56
Stage 4 disease
No	103	72	113	78	.21
Yes	40	28	31	22
Albumin (< 4 g/dL)*
No	45	31	42	29	.70
Yes	94	66	97	67
Unknown	4	3	5	3
Hemoglobin (< 10.5 g/dL)*
No	117	82	109	76	.15
Yes	18	13	27	19
Unknown	8	6	8	6
WBC count (≥ 15 000/mm³)*
No	114	80	112	78	.85
Yes	20	14	21	15
Unknown	9	6	11	8
Lymphocyte count (< 600/mm³ or < 8%)*
No	126	88	125	87	.81
Yes	9	6	10	7
Unknown	8	6	9	6
IPS (≥ 3)*
No	99	69	90	63	.26
Yes	44	31	53	37
Unknown	0	0	1	1
Histologic subtype*
Nodular sclerosis	115	80	108	75	.61
Mixed cellularity	18	13	20	14
Lymphocyte rich	3	2	5	3
Lymphocyte depleted	0	0	1	1
Unclassified	7	5	10	7
Treatment received
ABVD	74	52	70	49	.60
Stanford V	69	48	74	51
CD68 IHC expression
≤ 12.7% (CD68^low)	89	62	89	62	.94
> 12.7% (CD68^high)	54	38	55	38
CD163 IHC expression
≤ 16.8% (CD163^low)	90	63	78	54	.13
> 16.8% (CD163^high)	53	37	66	46
EBER ISH
Positive	25	17	24	17	.85
Negative	118	83	120	83

	Training		Validation		P
	n	%	n	%	P
Total	143		144
Age (≥ 45 y)
No	118	83	122	85	.61
Yes	25	17	22	15
Sex
Female	63	44	63	44	.96
Male	80	56	81	56
Stage 4 disease
No	103	72	113	78	.21
Yes	40	28	31	22
Albumin (< 4 g/dL)*
No	45	31	42	29	.70
Yes	94	66	97	67
Unknown	4	3	5	3
Hemoglobin (< 10.5 g/dL)*
No	117	82	109	76	.15
Yes	18	13	27	19
Unknown	8	6	8	6
WBC count (≥ 15 000/mm³)*
No	114	80	112	78	.85
Yes	20	14	21	15
Unknown	9	6	11	8
Lymphocyte count (< 600/mm³ or < 8%)*
No	126	88	125	87	.81
Yes	9	6	10	7
Unknown	8	6	9	6
IPS (≥ 3)*
No	99	69	90	63	.26
Yes	44	31	53	37
Unknown	0	0	1	1
Histologic subtype*
Nodular sclerosis	115	80	108	75	.61
Mixed cellularity	18	13	20	14
Lymphocyte rich	3	2	5	3
Lymphocyte depleted	0	0	1	1
Unclassified	7	5	10	7
Treatment received
ABVD	74	52	70	49	.60
Stanford V	69	48	74	51
CD68 IHC expression
≤ 12.7% (CD68^low)	89	62	89	62	.94
> 12.7% (CD68^high)	54	38	55	38
CD163 IHC expression
≤ 16.8% (CD163^low)	90	63	78	54	.13
> 16.8% (CD163^high)	53	37	66	46
EBER ISH
Positive	25	17	24	17	.85
Negative	118	83	120	83

P values are for comparing training with validation cohorts.

Pearson χ² test was performed with unknown or unclassified cases excluded.